Cessatech reports first patient dosed in pharmacokinetic trial in children of lead product candidate
Clinical trial 0206 will investigate the pharmacokinetics in children aged 1-17 undergoing elective surgical procedures. Primary aim of this trial is to obtain pharmacokinetic data from this age group and to demonstrate that CT001 nasal spray is feasible as premedication in children undergoing anaesthesia.Cessatech A/S announces that the pharmacokinetic trial (0206) in children has been initiated according to plan and that the first patient has been dosed. The trial is designed as a non-randomized, open-label study in 25 children aged 1-17 years needing premedication for placement of a